Alteogen's subsidiary, Alteogen Healthcare, held a board meeting on 31st of last month and appointed CEO Ko Jin-guk, the company announced on the 3rd. Alteogen Healthcare is an integrated corporation responsible for the sales and marketing of Alteogen's proprietary products.
CEO Ko graduated from the Department of Bioengineering at Yonsei University and completed an MBA at Yonsei University's Graduate School of Business. He was responsible for marketing and sales at LG Life Science and led new product launches and growth at Johnson & Johnson's pharmaceutical division in Korea.
CEO Ko will oversee the sales and marketing of Alteogen's proprietary products to be developed, starting with the recombinant hyaluronidase "Tergase." Former CEO Lee Jae-sang will contribute to the company's sustainable growth as an advisor.
Currently, Alteogen Healthcare is responsible for the sales and marketing of the growth hormone and adhesion prevention agent "Protescal" and the hyaluronidase product Tergase. Tergase received approval from the Ministry of Food and Drug Safety in July last year and aims to pass the pharmacy committee (DC) of more than 100 general hospitals this year. There are also plans to expand into overseas markets.
CEO Ko noted, "Based on Tergase's outstanding technology and market competitiveness, we will strive to achieve the number one position in the domestic market and focus on expanding into the global market and business areas."